INTRODUCTION: @entity1 with @entity0 have better cancer-related outcomes with the use of aromatase inhibitors (AIs), but the physiological suppression of @entity53 can negatively affect sexual functioning because of unpleasant urogenital and vaginal symptoms. Local health care practitioners have observed that the benefits of vaginal @entity251 in allaying these unpleasant symptoms in @entity1 with @entity0 are similar to the benefits of vaginal @entity172 in @entity1 without @entity0 . AIM: The aim of this study was to evaluate the effects of using a daily vaginal @entity251 cream on the reported sexual health quality of life in @entity1 with @entity0 taking AI therapy. METHODS: Thirteen postmenopausal @entity1 with @entity0 on AI therapy and experiencing symptoms of @entity250 were recruited from an oncology practice. The @entity1 were prescribed a 300  g @entity251 vaginal cream daily for 4 weeks. During the first study visit, a vaginal swab was obtained to rule out the presence of Candida species or @entity8439 in @entity1 . @entity1 with positive vaginal swabs were treated prior to starting the vaginal @entity251 therapy. MAIN OUTCOME MEASURE: The Female Sexual Function Index (FSFI) survey, measuring female sexual health quality of life, was administered during the first study visit and at the final study visit, after completing @entity251 therapy. RESULTS: Twelve @entity1 completed 4 weeks of daily vaginal @entity251 therapy. When compared with baseline FSFI scores, there was a statistically significant improvement for individual domain scores of desire (P = 0.000), arousal (P = 0.002), lubrication (P = 0.018), orgasm (P = 0.005), satisfaction (P = 0.001), and @entity158 (P = 0.000). Total domain scores reflecting sexual health quality of life also improved when compared with baseline (P = 0.000). CONCLUSIONS: The use of a compounded @entity251 vaginal cream applied daily for 4 weeks improves reported sexual health quality of life in @entity1 with @entity0 taking AIs. Dahir M and Travers-Gustafson D. @entity0 , aromatase inhibitor therapy, and sexual functioning: A pilot study of the effects of vaginal @entity251 therapy. Sex Med 2014;2:8-15.

@entity0 , aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal XXXX therapy.

@entity1 :: ('9606', 'Species') :: ['participants', 'women', 'patients', 'Women'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast cancer', 'breast cancer'] @entity8439 :: ('2702', 'Species') :: ['Gardnerella vaginalis'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity250 :: ('MESH:D012735', 'Disease') :: ['sexual dysfunction']
@entity251 :: (MESH:D013739,Chemical) :: ['testosterone']
